Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis

• Rozanolixizumab

  Participants receive rozanolixizumab based on investigator's medical judgement during Symptom-driven Cycles.

Primary

• Incidence of treatment-emergent adverse eventsUp to 2 years

• Incidence of treatment-emergent serious adverse eventsUp to 2 years

• Incidence of TEAEs leading to permanent withdrawal of study treatmentUp to 2 years

Secondary

• Change from Baseline in Myasthenia Gravis Impairment Index ocular scoreDay 43

• Change from Baseline in Myasthenia Gravis Activities of Daily Living ocular scoreDay 43

• Change from Baseline in Myasthenia Gravis Symptoms Patient-Reported Outcome ocular muscle weakness scale scoreDay 43

• Change from Baseline in Myasthenia Gravis Quality of Life 15-item Scale (revised version) total scoreDay 43

• Study participant who generalizes to Myasthenia Gravis Foundation of America class >=2 over timeUp to 2 years

• Change from Baseline in MGII total and generalized score over timeUp to 2 years

• Change from Baseline in MG-ADL total score over timeUp to 2 years